US 12,280,046 B2
Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease
Christine Ferrara-Cook, San Diego, CA (US); and Alan S. Krasner, San Diego, CA (US)
Assigned to CRINETICS PHARMACEUTICALS, INC., San Diego, CA (US)
Filed by Crinetics Pharmaceuticals, Inc., San Diego, CA (US)
Filed on Mar. 16, 2022, as Appl. No. 17/696,279.
Claims priority of provisional application 63/298,571, filed on Jan. 11, 2022.
Claims priority of provisional application 63/163,310, filed on Mar. 19, 2021.
Prior Publication US 2022/0313691 A1, Oct. 6, 2022
Int. Cl. A61K 31/496 (2006.01); A61K 9/00 (2006.01); A61K 31/573 (2006.01); A61P 5/08 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 9/0053 (2013.01); A61K 31/573 (2013.01); A61P 5/08 (2018.01)] 18 Claims
 
1. A method of treating Cushing's disease or ectopic ACTH syndrome (EAS) in a human, the method comprising administering to the human in need thereof a therapeutically effective amount of a compound having the structure of Compound 1, or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein treating Cushing's disease or EAS comprises reducing ACTH-stimulated cortisol levels in the human, and wherein ACTH-stimulated cortisol levels are reduced by at least about 35% in the human.